Download MendeleyDiscovery of novel quinoline sulphonamide derivatives as potent, selective and orally active ROR gamma inverse agonists.
Amaudrut, J., Argiriadi, M.A., Barth, M., Breinlinger, E.C., Bressac, D., Broqua, P., Calderwood, D.J., Chatar, M., Cusack, K.P., Gauld, S.B., Jacquet, S., Kamath, R.V., Kort, M.E., Lepais, V., Luccarini, J.M., Masson, P., Montalbetti, C., Mounier, L., Potin, D., Poupardin, O., Rouaud, S., Spitzer, L., Wallace, C.D.(2019) Bioorg Med Chem Lett 29: 1799-1806
- PubMed: 31101472
- DOI: https://doi.org/10.1016/j.bmcl.2019.05.015
- Primary Citation of Related Structures:
6Q2W - PubMed Abstract:
A high-throughput screen against Inventiva's compound library using a Gal4/RORγ-LBD luciferase reporter gene assay led to the discovery of a new series of quinoline sulphonamides as RORγ inhibitors, eventually giving rise to a lead compound having an interesting in vivo profile after oral administration. This lead was evaluated in a target engagement model in mouse, where it reduced IL-17 cytokine production after immune challenge. It also proved to be active in a multiple sclerosis model (EAE) where it reduced the disease score. The synthesis, structure activity relationship (SAR) and biological activity of these derivatives is described herein.
Organizational Affiliation:
Inventiva, 50 rue de Dijon, 21121 Daix, France.
